
https://www.science.org/content/blog-post/lessons-new-medicinal-chemist
# Lessons For a New Medicinal Chemist (June 2012)

## 1. SUMMARY  
The author reflects on the steep learning curve he faced when moving from a synthetic‑organic background into medicinal chemistry in the early‑1990s. He lists eight concrete “lessons” that shaped his practice:

1. **Metabolism is wild.** Cytochrome P450 enzymes can perform transformations (e.g., benzene epoxidation, piperazine ring opening) that most synthetic chemists never encounter.  
2. **Physicochemical limits matter.** The “Lipinski”‑type rules are a reality check: you cannot keep adding weight or lipophilicity without paying a penalty in clearance, solubility, or toxicity.  
3. **Assay data are noisy.** Enzyme, cell‑based, and animal assays each have intrinsic variability; the hierarchy of error (enzyme < cell < animal) must be kept in mind.  
4. **Time is money.** In industry you are paid for thinking, not for grinding out reactions; buying reagents or outsourcing can be more efficient than making everything yourself.  
5. **Work‑hour discipline pays off.** Structured planning beats the “work‑all‑hours” habit that stretches projects.  
6. **Compound quality drives data quality.** Dirty or poorly characterized material yields unreliable results, compounding the assay noise already present.  
7. **Chemistry is a means, not an end.** The ultimate goal is a marketable therapeutic; everything else (elegant synthesis, academic accolades) is secondary to that objective.  
8. **Synthetic elegance is irrelevant to biology.** Whether a molecule is made by a sophisticated route or a crude, high‑yielding one, the biological system only cares about the molecule’s pharmacological profile. Speed, ease, and reproducibility are the prized virtues.

The piece is essentially a “field‑notes” guide for newcomers, emphasizing pragmatic thinking over academic idealism.

---

## 2. HISTORY  

### Metabolism & P450 Modeling  
Since 2012, computational tools for predicting P450 metabolism (e.g., MetaSite, StarDrop, and open‑source models in RDKit) have become routine in early‑stage projects. The industry has not “solved” the wildness of metabolism, but the ability to flag likely soft spots before synthesis has reduced late‑stage failures. Experimental microsomal screens remain standard, confirming the author’s point that metabolic transformations are still a major source of attrition.

### Physicochemical Rules  
The Lipinski “Rule‑of‑Five” remains a baseline filter for oral drugs, but the field has broadened. The “Rule‑of‑Three” guides fragment‑based design, while “beyond‑Rule‑of‑Five” (bRo5) chemistry—macrocycles, PROTACs, and peptide‑like molecules—has grown into a sizable sub‑area. Nonetheless, the core lesson that excessive MW or logP incurs liability has held true; most FDA‑approved small molecules (2020‑2025) still sit within the classic ranges.

### Assay Variability & Data Science  
High‑throughput screening (HTS) platforms have improved assay robustness, and statistical best practices (replicates, Z′‑factor monitoring) are now codified in SOPs. Yet the hierarchy of variability described (enzyme < cell < in‑vivo) remains unchanged, and modern drug‑discovery teams routinely incorporate assay error into SAR decisions (e.g., Bayesian models that weight data by confidence).

### Time‑Efficiency & Outsourcing  
The “buy‑instead‑make” mindset has accelerated. Contract research organizations (CROs) now offer rapid parallel synthesis (e.g., “on‑demand” libraries, AI‑guided route scouting) that many companies use for early SAR. Automation (e.g., Chemspeed, Synthace) and flow chemistry have also reduced hands‑on time, aligning with the author’s call to prioritize thinking over manual work.

### Working Hours & Project Management  
Project‑management software (Jira, Asana) and “lean” methodologies have been adopted widely in pharma R&D, encouraging defined work‑blocks and reducing the “always‑on” culture that plagued older labs. Remote‑work policies (especially post‑COVID‑19) have further formalized structured schedules.

### Compound Quality  
Regulatory expectations for impurity profiling (ICH Q3) have tightened, and analytical platforms (LC‑HRMS, NMR‑based purity checks) are now standard before any biological testing. The industry’s “clean‑compound‑first” culture directly reflects the author’s lesson.

### Chemistry as a Means & the Rise of Biologics  
Biologics have indeed exploded: in 2022, > 50 % of new FDA approvals were biologics or antibody‑drug conjugates (ADCs). However, small‑molecule drugs still dominate numerically (≈ 70 % of NMEs). The author’s warning that chemistry is a means to a marketable drug remains accurate; many companies now run “dual‑track” programs (small molecule + biologic) to hedge bets.

### Synthetic Elegance vs. Pragmatism  
The “speed‑first” synthesis philosophy has become institutionalized. Rapid “medicinal chemistry sprint” cycles (often < 2 weeks from design to assay) are the norm, supported by automated parallel synthesis and rapid purification (e.g., flash chromatography robots). Elegant, low‑yielding routes are rarely pursued unless they unlock a unique scaffold.

---

## 3. PREDICTIONS  

| Prediction (implicit in the article) | What actually happened | Assessment |
|---|---|---|
| **Metabolic transformations will continue to surprise synthetic chemists.** | P450‑mediated metabolism remains a major cause of clinical failure; computational prediction tools have improved but cannot fully replace experimental data. | Correct – the unpredictability persists. |
| **Physical‑property limits (MW, logP) will constrain drug design.** | Most oral drugs approved 2012‑2025 still obey Lipinski‑type limits; bRo5 molecules are growing but are a minority and often require special delivery strategies. | Largely correct; the rule remains a useful filter. |
| **Assay error will be a constant, requiring careful interpretation.** | Statistical rigor in HTS and cell assays has increased, but variability across assay types is still a key consideration; data‑driven SAR now explicitly models error. | Accurate. |
| **Time‑money pressure will push chemists toward buying or outsourcing reagents.** | Outsourcing of synthesis, use of commercial building blocks, and AI‑guided route planning have become standard; “make‑or‑buy” decisions are routinely quantified. | Correct. |
| **Working hours will become more structured and efficient.** | Lean project management, defined sprint cycles, and remote‑work policies have reduced “always‑on” lab culture in many companies. | Generally true, though some high‑throughput labs still run 24 h shifts. |
| **Dirty compounds will produce dirty data, reinforcing the need for purity.** | Regulatory and internal standards now demand > 95 % purity before biological testing; impurity‑driven artifacts are well‑documented. | Correct. |
| **Chemistry will be a means, not an end; biologics will become a major alternative.** | Biologics now account for > 50 % of new approvals; small‑molecule pipelines still dominate but are increasingly integrated with biologic strategies (e.g., ADCs). | Accurate. |
| **Synthetic elegance will be secondary to speed, ease, and reproducibility.** | Rapid “medicinal chemistry sprint” cycles, automated synthesis, and high‑throughput purification are now industry standards; elegant routes are reserved for IP‑critical or scale‑up stages. | Correct. |

Overall, the author’s implicit forecasts have held up remarkably well. The few areas where the industry has diverged (e.g., growth of bRo5 molecules, AI‑driven design) are extensions rather than contradictions of the core lessons.

---

## 4. INTEREST  
**Rating: 7/10**  

The article captures timeless, practical wisdom that remains directly applicable to modern drug discovery, making it a solid reference for trainees. It is not groundbreaking science, but its distilled, experience‑based insights give it lasting relevance.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120608-lessons-new-medicinal-chemist.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_